• Context Therapeutics Advances First-in-Human CT-202 Trial, Setting Up a New Nectin-4 Oncology Catalyst TipRanks Thu, 09 Jul 2026 16:42:07 GMT
• Context Therapeutics stock rises on Russell index inclusion Investing.com Mon, 06 Jul 2026 20:38:27 GMT
• Context Therapeutics Joins Russell 2000, Russell 3000 Indexes Moomoo Mon, 06 Jul 2026 20:17:54 GMT
• Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes Yahoo Finance Mon, 06 Jul 2026 20:07:00 GMT
• Context Therapeutics joins Russell 2000 and 3000 indexes Stock Titan Mon, 06 Jul 2026 20:07:00 GMT
• Diluted net income available to common stockholders of Context Therapeutics, Inc. – DUS:6K9 TradingView Mon, 06 Jul 2026 05:33:50 GMT
• Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish Yahoo Finance Sun, 05 Jul 2026 22:08:41 GMT
• context therapeutics (cntx) gains 7.46% as stock tests key resistance at $0.68 - social sentiment dars.gov.et Fri, 03 Jul 2026 15:43:15 GMT
• LYRA stock tracks Lyra Therapeutics after recent filing context. ad-hoc-news.de Fri, 03 Jul 2026 13:27:58 GMT
• Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 2000 Index marketscreener.com Mon, 29 Jun 2026 18:57:01 GMT
• enterprise value to ebitda forward of context therapeutics, inc. – mun:6k9 TradingView Mon, 29 Jun 2026 01:55:16 GMT
• Context Therapeutics Shareholders Approve Stock Increase and Directors The Globe and Mail Sat, 27 Jun 2026 20:32:00 GMT
• Price to book forward of Context Therapeutics Inc. – NASDAQ:CNTX TradingView Sat, 27 Jun 2026 19:51:46 GMT
• Context Therapeutics Shareholders Approve Stock Increase and Directors TipRanks Fri, 26 Jun 2026 21:01:38 GMT
• context therapeutics (cntx) director linda west awarded 45k stock options Stock Titan Fri, 26 Jun 2026 20:21:38 GMT
• Context Therapeutics (CNTX) director awarded 45,000 stock options at $0.576 Stock Titan Fri, 26 Jun 2026 07:00:00 GMT
• Director at Context Therapeutics (CNTX) receives 45,000 stock options award Stock Titan Fri, 26 Jun 2026 07:00:00 GMT
• Context Therapeutics (CNTX) director receives grant of 45,000 stock options at $0.576 Stock Titan Fri, 26 Jun 2026 07:00:00 GMT
• Director Philip Kantoff receives 45,000 CNTX stock options at $0.576 exercise price Stock Titan Fri, 26 Jun 2026 07:00:00 GMT
• Context Therapeutics (NASDAQ: CNTX) wins approval to lift share authorization to 300M Stock Titan Fri, 26 Jun 2026 07:00:00 GMT
• Context Therapeutics, Inc. Actuals & Estimates (NASDAQ:CNTX) TradingView Fri, 26 Jun 2026 06:57:43 GMT
• price to sales forward of context therapeutics inc. – nasdaq:cntx TradingView Fri, 26 Jun 2026 03:36:40 GMT
• price to earnings forward of context therapeutics inc. – nasdaq:cntx TradingView Thu, 25 Jun 2026 07:28:49 GMT
• Context Therapeutics (CNTX) Rallies 5% as Biotech Stock Tests Key Resistance - MFI Overbought dars.gov.et Sun, 21 Jun 2026 07:00:00 GMT
• context therapeutics inc (cntx) financial health: profitability & balance sheet analysis TradingKey Thu, 18 Jun 2026 10:20:14 GMT
• context therapeutics inc (cntx) risk assessment: volatility, financial risk & investment risk TradingKey Thu, 18 Jun 2026 10:19:46 GMT
• context therapeutics inc (cntx) valuation: pe, pb & fair value analysis TradingKey Thu, 18 Jun 2026 10:17:14 GMT
• context therapeutics inc (cntx) earnings forecast: future eps & revenue growth estimates TradingKey Thu, 18 Jun 2026 09:55:16 GMT
• context therapeutics inc (cntx) technical analysis: support, resistance, indicators & moving averages TradingKey Thu, 18 Jun 2026 09:50:54 GMT
• Context Therapeutics Inc (CNTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution TradingKey Wed, 17 Jun 2026 22:51:51 GMT
• context therapeutics inc (cntx) dividends & stock splits: historical payouts and event timeline TradingKey Wed, 17 Jun 2026 22:21:40 GMT
• context therapeutics inc (cntx) shareholder structure: major shareholders & institutional holdings TradingKey Wed, 17 Jun 2026 21:56:54 GMT
• cntx maintained by maxim group -- price target lowered to $4.00 GuruFocus Wed, 17 Jun 2026 01:37:52 GMT
• cntx hits worst day in history after ovarian cancer trial data — but analysts see buying opportunity in dip MSN Tue, 16 Jun 2026 18:40:38 GMT
• a quick look at today's ratings for context therapeutics(cntx.us), with a forecast between $5 to $7 Moomoo Tue, 16 Jun 2026 15:16:27 GMT
• revenue per share of context therapeutics, inc. – dus:6k9 TradingView Tue, 16 Jun 2026 14:29:49 GMT
• context therapeutics price target lowered to $4 from $8 at maxim TipRanks Tue, 16 Jun 2026 14:24:59 GMT
• basic earnings per share (basic eps) of context therapeutics, inc. – dus:6k9 TradingView Tue, 16 Jun 2026 14:07:09 GMT
• cost of goods sold of context therapeutics, inc. – dus:6k9 TradingView Tue, 16 Jun 2026 13:43:36 GMT
• Context Therapeutics Reports 29% Response Rate for CTIM-76 in Platinum-Resistant Ovarian Cancer Phase 1 Trial BioPharm International Tue, 16 Jun 2026 07:00:00 GMT
• CNTX Maintained by Maxim Group -- Price Target Lowered to $4.00 GuruFocus Tue, 16 Jun 2026 07:00:00 GMT
• context therapeutics highlights positive ctim-76 phase 1 data The Globe and Mail Tue, 16 Jun 2026 07:00:00 GMT
• analysts offer insights on healthcare companies: dyadic international (dyai) and context therapeutics (cntx) The Globe and Mail Tue, 16 Jun 2026 07:00:00 GMT
• context therapeutics inc (cntx) technical analysis: support, resistance, indicators & moving averages TradingKey Tue, 16 Jun 2026 07:00:00 GMT
• context therapeutics selloff brings buying opportunity, says jonesresearch TipRanks Mon, 15 Jun 2026 21:08:45 GMT
• charles zhu reiterates buy on context therapeutics, citing encouraging ctim-76 efficacy, favorable safety, and de‑risked developme... TipRanks Mon, 15 Jun 2026 20:46:53 GMT
• context stock reaction ‘overdone’ after ctim-76 data, says h.c. wainwright TipRanks Mon, 15 Jun 2026 17:14:56 GMT
• context therapeutics rises on interim phase 1 ovarian cancer data grafa.com Mon, 15 Jun 2026 14:38:35 GMT
• Context Therapeutics announces ‘positive’ results from Phase 1 CTIM-76 trial TipRanks Mon, 15 Jun 2026 10:43:27 GMT
• New CTIM-76 data show tumor responses in platinum-resistant ovarian cancer Stock Titan Mon, 15 Jun 2026 07:00:00 GMT
• Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76 GlobeNewswire Mon, 15 Jun 2026 07:00:00 GMT
• Context Therapeutics (NASDAQ: CNTX) shows early CTIM-76 activity in platinum-resistant ovarian cancer Stock Titan Mon, 15 Jun 2026 07:00:00 GMT
• Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study Benzinga Mon, 15 Jun 2026 07:00:00 GMT
• CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip Stocktwits Mon, 15 Jun 2026 07:00:00 GMT
• Context reports positive interim Phase 1 CTIM-76 data with 29% ORR in PROC, low CRS TradingView Mon, 15 Jun 2026 07:00:00 GMT
• Context Therapeutics Reports Encouraging Phase 1 Results for CTIM-76 T Cell Engager in Platinum-Resistant Ovarian Cancer – Minicha... Minichart Mon, 15 Jun 2026 07:00:00 GMT
• Boris Peaker Reiterates Buy on Context Therapeutics, Maintains $7 Price Target on Promising CTIM-76 Data and Attractive Risk/Rewar... TipRanks Mon, 15 Jun 2026 07:00:00 GMT
• context therapeutics to proceed with next development phase of ctim-76 in ovarian cancer Moomoo Mon, 15 Jun 2026 07:00:00 GMT
• cntx: ctim-76 shows 29% response and strong safety in late-line platinum-resistant ovarian cancer TradingView Mon, 15 Jun 2026 07:00:00 GMT
• context therapeutics grants new-hire equity award under nasdaq rule MyChesCo Sun, 14 Jun 2026 21:04:56 GMT
• CNTX Q1 2026 Earnings: Narrower Loss Beats Estimates as Context Therapeutics Advances Clinical Pipeline dars.gov.et Fri, 12 Jun 2026 07:00:00 GMT
• Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and Context Therapeutics (CNTX) The Globe and Mail Wed, 10 Jun 2026 07:00:00 GMT
• 12 health care stocks moving in tuesday's after-market session Benzinga Tue, 09 Jun 2026 21:06:04 GMT
• Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Tue, 09 Jun 2026 07:00:00 GMT
• jonestrading maintains context therapeutics(cntx.us) with buy rating, maintains target price $7 Moomoo Tue, 09 Jun 2026 07:00:00 GMT
• context therapeutics (cntx) sheds 13.8% as stock tests key support level - low beta factor newsline.com Sat, 06 Jun 2026 00:47:28 GMT
• 12 health care stocks moving in friday's after-market session Benzinga Fri, 05 Jun 2026 21:06:15 GMT
• cntx stock price, quote & chart | context therapeutics inc (nasdaq:cntx) ChartMill Fri, 05 Jun 2026 07:00:00 GMT
• CNTX: Lead T-cell engager shows early promise in ovarian cancer; key data updates expected soon TradingView Wed, 03 Jun 2026 07:00:00 GMT
• piper sandler maintains context therapeutics(cntx.us) with buy rating, maintains target price $7 Moomoo Tue, 02 Jun 2026 07:00:00 GMT
• cntx stock price, quote & chart | context therapeutics inc (nasdaq:cntx) ChartMill Tue, 02 Jun 2026 07:00:00 GMT
• context therapeutics q1 2026 earnings: narrowing losses with eps beat of 24.81% - profit warning alert The Legal Advocate Sat, 30 May 2026 02:35:24 GMT
• context therapeutics (cntx) price target increased by 13.33% to 5.78 MSN Sat, 30 May 2026 01:36:23 GMT
• context therapeutics (cntx) edges higher, tests resistance near $3.00 - inverse etf flow The Legal Advocate Sat, 30 May 2026 00:37:26 GMT
• context therapeutics (cntx) holds near support as biotech sector faces headwinds - volume rate change The Legal Advocate Fri, 29 May 2026 14:47:14 GMT
• Context Therapeutics (CNTX) Edges Higher, Tests Resistance Near $3.00 - Money Flow Index dars.gov.et Fri, 29 May 2026 07:00:00 GMT
• context therapeutics (cntx) edges higher as shares test resistance near $3.00 - moving average ribbon newsline.com Fri, 29 May 2026 07:00:00 GMT
• context therapeutics q1 2026 earnings: narrowing losses with eps beat of 24.81% - low growth earnings newsline.com Fri, 29 May 2026 07:00:00 GMT
• cntx q1 2026 earnings: narrower-than-expected loss drives positive surprise - segment revenue breakdown The Legal Advocate Fri, 29 May 2026 03:30:36 GMT
• context therapeutics (cntx) drops 5% as stock tests key support near $2.69 - high conviction picks newsline.com Thu, 28 May 2026 07:00:00 GMT
• cntx q1 2026 earnings: narrower loss surprises, shares advance over 13% - annual report newsline.com Thu, 28 May 2026 07:00:00 GMT
• context therapeutics to present at jefferies global healthcare conference geneonline.com Wed, 27 May 2026 22:30:25 GMT
• Context Therapeutics to Present at the Jefferies Global Healthcare Conference GlobeNewswire Wed, 27 May 2026 07:00:00 GMT
• biotech context therapeutics presents solid-tumor antibody work at jefferies Stock Titan Wed, 27 May 2026 07:00:00 GMT
• cntx stock price, quote & chart | context therapeutics inc (nasdaq:cntx) ChartMill Wed, 27 May 2026 07:00:00 GMT
• context therapeutics (cntx) surges over 8% amid renewed buying interest above key support - fear greed extreme newsline.com Mon, 25 May 2026 07:00:00 GMT
• william blair maintains context therapeutics(cntx.us) with buy rating 富途牛牛 Sun, 24 May 2026 12:41:30 GMT
• context therapeutics (cntx) gets a buy from piper sandler The Globe and Mail Sat, 23 May 2026 11:36:00 GMT
• cntx q1 2026 earnings: context therapeutics beats eps estimates with narrower-than-expected loss - gaap earnings report The Legal Advocate Sat, 23 May 2026 07:00:00 GMT
• Piper Sandler Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $7 Moomoo Fri, 22 May 2026 07:00:00 GMT
• context therapeutics maintained at buy as advancing clinical pipeline and upcoming catalysts support unchanged $5 price target TipRanks Thu, 21 May 2026 03:36:47 GMT
• maxim group maintains context therapeutics(cntx.us) with buy rating, maintains target price $8 Moomoo Wed, 20 May 2026 18:10:53 GMT
• maxim group maintains context therapeutics(cntx.us) with buy rating, raises target price to $8 富途牛牛 Tue, 19 May 2026 14:31:00 GMT
• Context Therapeutics Decline Means Insider Profits Down To US$237k simplywall.st Tue, 19 May 2026 07:00:00 GMT
• analyst lifts price target and reiterates buy on context therapeutics’ bispecific pipeline progress and strengthened financial pos... TipRanks Tue, 19 May 2026 07:00:00 GMT
• context therapeutics secures full rights to ct-202 from bioatla with license buyout, phase 1 trial planned for q3 2026 minichart.com.sg Tue, 19 May 2026 07:00:00 GMT
• context therapeutics secures full rights to ct-202 under revised bioatla deal Moomoo Mon, 18 May 2026 18:14:06 GMT
• context therapeutics enters license agreement amendment with bioatla TipRanks Mon, 18 May 2026 11:51:21 GMT
• Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 GlobeNewswire Mon, 18 May 2026 07:00:00 GMT
• Context Therapeutics Pays $6.5 Million to Make BioAtla Antibody Licenses Perpetual and Royalty-Free TradingView Mon, 18 May 2026 07:00:00 GMT
• context to pay $6.5m for full ct-202 rights by aug. 1, 2026 Stock Titan Mon, 18 May 2026 07:00:00 GMT
• context therapeutics (cntx) secures fully paid-up, non-terminable ct-202 license Stock Titan Mon, 18 May 2026 07:00:00 GMT
• context therapeutics secures full rights to antibody assets TipRanks Mon, 18 May 2026 07:00:00 GMT
• context therapeutics inc. announces amendment to license agreement for ct-202, securing full economic rights Quiver Quantitative Mon, 18 May 2026 07:00:00 GMT
• analyst charles zhu reiterates buy on context therapeutics, citing favorable ct-202 license economics and key ctim-76 ovarian canc... TipRanks Mon, 18 May 2026 07:00:00 GMT
• context therapeutics advances cancer drug pipeline toward data readouts MyChesCo Sat, 16 May 2026 07:00:00 GMT
• context therapeutics (cntx) crushes q1 2026 estimates — eps $-0.09 tops views - slow growth warning newsline.com Fri, 15 May 2026 07:00:00 GMT
• context therapeutics (cntx) joint filing shows 2.44% ownership by great point partners Stock Titan Fri, 15 May 2026 07:00:00 GMT
• context therapeutics (cntx) slips -6.87%, testing $2.06 support 2026-05-15 - sign of strength The Legal Advocate Fri, 15 May 2026 07:00:00 GMT
• blue owl capital holdings (cntx) discloses 5.54% ownership in context therapeutics Stock Titan Thu, 14 May 2026 07:00:00 GMT
• octagon, master fund, ting jia file 5.25m-share holding in cntx (5.7%) Stock Titan Thu, 14 May 2026 07:00:00 GMT
• MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Respo... Yahoo Finance Tue, 12 May 2026 07:00:00 GMT
• avidity entities hold 8.7% of context therapeutics (nasdaq: cntx) Stock Titan Tue, 12 May 2026 07:00:00 GMT
• lifesci capital issues positive estimate for cntx earnings MarketBeat Mon, 11 May 2026 09:28:56 GMT
• hc wainwright issues optimistic outlook for cntx earnings MarketBeat Mon, 11 May 2026 07:33:25 GMT
• lifesci capital maintains context therapeutics(cntx.us) with buy rating, maintains target price $6 Moomoo Sun, 10 May 2026 04:25:38 GMT
• [schedule 13g/a] context therapeutics inc. amended passive investment disclosure Stock Titan Fri, 08 May 2026 21:00:57 GMT
• a quick look at today's ratings for context therapeutics(cntx.us), with a forecast between $5 to $7 Moomoo Fri, 08 May 2026 18:30:29 GMT
• piper sandler sticks to its buy rating for context therapeutics (cntx) The Globe and Mail Fri, 08 May 2026 12:08:00 GMT
• cntx context therapeutics q4 loss widens, misses estimates by 29%; shares drop 3.3% on earnings disappointment. newsline.com Fri, 08 May 2026 07:00:00 GMT
• what makes context therapeutics (cntx) a compelling holding for the long term (-3.32%) 2026-05-08 - parabolic sar newsline.com Fri, 08 May 2026 07:00:00 GMT
• soleus entities (cntx) report 6.96m shares, 7.6% stake disclosed Stock Titan Fri, 08 May 2026 07:00:00 GMT
• what is hc wainwright's estimate for cntx fy2030 earnings? MarketBeat Fri, 08 May 2026 07:00:00 GMT
• context therapeutics inc. (cntx) eps diluted (ttm) Zacks Investment Research Fri, 08 May 2026 02:58:30 GMT
• analysts are bullish on top healthcare stocks: trevi therapeutics (trvi), eyepoint pharmaceuticals (eypt) The Globe and Mail Thu, 07 May 2026 07:00:00 GMT
• context therapeutics reports first quarter 2026 operating and financial results The Manila Times Thu, 07 May 2026 07:00:00 GMT
• a quick look at today's ratings for context therapeutics(cntx.us), with a forecast between $5 to $7 Moomoo Thu, 07 May 2026 07:00:00 GMT
• context therapeutics maintained at buy as advancing clinical pipeline and upcoming catalysts support unchanged $5 price target TipRanks Thu, 07 May 2026 07:00:00 GMT
• context therapeutics inc. reports earnings results for the first quarter ended march 31, 2026 marketscreener.com Wed, 06 May 2026 20:10:00 GMT
• Context Therapeutics Reports First Quarter 2026 Operating and Financial Results GlobeNewswire Wed, 06 May 2026 07:00:00 GMT
• cancer drug developer maps 3 trial milestones as cash lasts to 2027 Stock Titan Wed, 06 May 2026 07:00:00 GMT
Context Therapeutics Inc.(NASDAQ:CNTX) 
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a selective potent antagonist of the progesterone receptor that is linked to resis...
Website: http://www.contexttherapeutics.com
Founded: 2015
CEO: Martin Lehr
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends